Coeptis Therapeutics (NASDAQ:ZSQR) Announces Earnings Results

Coeptis Therapeutics (NASDAQ:ZSQR) released its earnings results on Thursday. The company reported ($0.65) earnings per share (EPS) for the quarter, FiscalAI reports. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%. The firm had revenue of $0.11 million during the quarter.

Coeptis Therapeutics Trading Down 6.0%

Shares of NASDAQ:ZSQR traded down $0.59 during mid-day trading on Friday, hitting $9.25. The company had a trading volume of 173,002 shares, compared to its average volume of 73,109. The firm has a fifty day moving average price of $12.66 and a 200 day moving average price of $13.72. The company has a market capitalization of $57.54 million, a PE ratio of -3.10 and a beta of -0.09. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.16 and a quick ratio of 4.16. Coeptis Therapeutics has a one year low of $6.80 and a one year high of $21.41.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC raised its stake in Coeptis Therapeutics by 12.6% during the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock worth $600,000 after buying an additional 4,721 shares during the period. State Street Corp raised its stake in Coeptis Therapeutics by 35.0% during the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock worth $382,000 after buying an additional 6,962 shares during the period. Marshall Wace LLP acquired a new position in Coeptis Therapeutics during the 4th quarter worth approximately $259,000. Steward Partners Investment Advisory LLC raised its stake in Coeptis Therapeutics by 100.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock worth $71,000 after buying an additional 2,500 shares during the period. Finally, Yorkville Advisors Global LP acquired a new position in Coeptis Therapeutics during the 3rd quarter worth approximately $140,000. 13.88% of the stock is owned by institutional investors and hedge funds.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.